On 29 July 2021, the CMA announced that it had imposed a fine of £101 million on Advanz Pharma for abusing its dominant position by charging excessive and unfair prices for liothyronine tablets between 2009 and 2017.
On 29 July 2021, the CMA announced that it had imposed a fine of £101 million on Advanz Pharma for abusing its dominant position by charging excessive and unfair prices for liothyronine tablets between 2009 and 2017.